Last reviewed · How we verify
XP13512 (GSK1838262)
XP13512 is a voltage-gated sodium channel blocker.
XP13512 is a voltage-gated sodium channel blocker. Used for Partial-onset seizures.
At a glance
| Generic name | XP13512 (GSK1838262) |
|---|---|
| Sponsor | XenoPort, Inc. |
| Drug class | sodium channel blocker |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the activity of voltage-gated sodium channels, which are involved in the transmission of nerve impulses. This can help to reduce the frequency of seizures in patients with epilepsy.
Approved indications
- Partial-onset seizures
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
- Somnolence
Key clinical trials
- Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study (PHASE4)
- Simulated Driving Study in Restless Legs Syndrome (PHASE2)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment (PHASE2)
- XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. (PHASE3)
- Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome (PHASE2)
- XP13512 vs. Placebo in Patients With Restless Legs Syndrome. (PHASE3)
- A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) (PHASE2)
- A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |